In both the European Union (“EU”) and the United States (“US”), there is an increasing focus on showing value for innovative medicines. While the mechanisms differ, this demand stems from the same developments - decreasing funds available to payers and increasing prices of innovative medicines. The payers’ responses are similar as well: proposals to limit prices and restrict availability and requiring proof of value of the innovative medicine before there will be an agreement to pay for it at any level.